Scuffham, Paul A.; Chaplin, Stephen - In: PharmacoEconomics 22 (2004) 8, pp. 525-535
Aims: To estimate the costs, benefits and cost effectiveness, from the UK NHS perspective, of fluvastatin (relative to no HMG-CoA reductase inhibitor [statin]) for the secondary prevention of major adverse cardiac events following a successful first percutaneous coronary intervention (PCI)....